ABIVAX Société Anonyme (AAVXF)
USD 11.05
(0.0%)
USD 11.05
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -127.37 Million EUR | -133.02% |
| 2022 | -56.64 Million EUR | -33.09% |
| 2021 | -42.56 Million EUR | -11.98% |
| 2020 | -38 Million EUR | -14.15% |
| 2019 | -33.29 Million EUR | -74.25% |
| 2018 | -19.1 Million EUR | -35.04% |
| 2017 | -14.15 Million EUR | 22.41% |
| 2016 | -18.23 Million EUR | 0.1% |
| 2015 | -18.25 Million EUR | -106.11% |
| 2014 | -8.85 Million EUR | -19.73% |
| 2013 | -7.39 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -39.99 Million EUR | 0.0% |
| 2024 Q1 | -39.99 Million EUR | 11.21% |
| 2023 Q3 | -45.08 Million EUR | -14.05% |
| 2023 FY | -131.99 Million EUR | -133.02% |
| 2023 Q1 | -18.64 Million EUR | 50.97% |
| 2023 Q2 | -39.53 Million EUR | -112.1% |
| 2023 Q4 | -45.04 Million EUR | 0.09% |
| 2022 Q3 | -18.09 Million EUR | 2.85% |
| 2022 FY | -56.64 Million EUR | -33.09% |
| 2022 Q4 | -38.02 Million EUR | -110.14% |
| 2022 Q2 | -18.62 Million EUR | -147.57% |
| 2022 Q1 | -7.52 Million EUR | 70.71% |
| 2021 Q4 | -25.68 Million EUR | -127.32% |
| 2021 Q1 | -13.26 Million EUR | 43.29% |
| 2021 Q2 | -26.53 Million EUR | -100.08% |
| 2021 FY | -42.56 Million EUR | -11.98% |
| 2021 Q3 | -11.3 Million EUR | 57.41% |
| 2020 Q4 | -23.38 Million EUR | -99.99% |
| 2020 Q2 | -16.21 Million EUR | -100.0% |
| 2020 Q3 | -11.69 Million EUR | 27.88% |
| 2020 Q1 | -8.1 Million EUR | 49.55% |
| 2020 FY | -38 Million EUR | -14.15% |
| 2019 Q3 | -8.03 Million EUR | 53.31% |
| 2019 Q4 | -16.06 Million EUR | -100.01% |
| 2019 FY | -33.29 Million EUR | -74.25% |
| 2019 Q1 | -8.61 Million EUR | -63.42% |
| 2019 Q2 | -17.2 Million EUR | -99.76% |
| 2018 FY | -19.1 Million EUR | -35.04% |
| 2018 Q3 | -5.27 Million EUR | -23.05% |
| 2018 Q2 | -4.28 Million EUR | 0.0% |
| 2018 Q1 | -4.28 Million EUR | -27.01% |
| 2018 Q4 | -5.27 Million EUR | 0.0% |
| 2017 Q1 | -3.7 Million EUR | 2.81% |
| 2017 Q2 | -3.7 Million EUR | 0.0% |
| 2017 Q3 | -3.37 Million EUR | 8.91% |
| 2017 Q4 | -3.37 Million EUR | 0.0% |
| 2017 FY | -14.15 Million EUR | 22.41% |
| 2016 Q2 | -5.3 Million EUR | 0.0% |
| 2016 FY | -18.23 Million EUR | 0.1% |
| 2016 Q3 | -3.8 Million EUR | 28.24% |
| 2016 Q1 | -5.3 Million EUR | -4.61% |
| 2016 Q4 | -3.8 Million EUR | 0.0% |
| 2015 Q1 | -4.05 Million EUR | -88.64% |
| 2015 Q2 | -4.05 Million EUR | 0.0% |
| 2015 Q3 | -5.07 Million EUR | -25.2% |
| 2015 Q4 | -5.07 Million EUR | 0.0% |
| 2015 FY | -18.25 Million EUR | -106.11% |
| 2014 FY | -8.85 Million EUR | -19.73% |
| 2014 Q4 | -2.14 Million EUR | 0.0% |
| 2014 Q2 | -378.5 Thousand EUR | 0.0% |
| 2014 Q1 | -378.5 Thousand EUR | 0.0% |
| 2014 Q3 | -2.14 Million EUR | -467.64% |
| 2013 FY | -7.39 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -77.438% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 2691.676% |
| SQZ Biotechnologies Company | -75.82 Million USD | -67.987% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -613.711% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 255.618% |
| Mesoblast Limited | -84.14 Million USD | -51.373% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -8192.444% |
| Genus plc | 6.4 Million USD | 2090.25% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 1407.432% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -13576.051% |
| Marizyme, Inc. | -34.08 Million USD | -273.684% |
| ContraFect Corporation | -56.88 Million USD | -123.903% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -1425.461% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -2696.568% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -8985.365% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -4368.538% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -4530.442% |
| MultiCell Technologies, Inc. | -722.81 USD | -17622235.053% |
| Accustem Sciences Inc. | -3.74 Million USD | -3299.94% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -115.928% |
| EV Biologics, Inc. | -483.06 Thousand USD | -26268.458% |
| Q BioMed Inc. | -3.44 Million USD | -3596.756% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 3698.192% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -32596.563% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -4747.762% |
| Biomind Labs Inc. | -1 Million USD | -12516.444% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -2510.408% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -1816.0% |
| Skye Bioscience, Inc. | -13.67 Million USD | -831.67% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -6312.149% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -425167.094% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -2425.056% |
| IMV Inc. | -38.67 Million USD | -229.379% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -702.635% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -6490.88% |
| GB Sciences, Inc. | -1.42 Million USD | -8866.927% |
| Alpha Cognition Inc. | -9.7 Million USD | -1212.397% |
| HST Global, Inc. | -140.9 Thousand USD | -90297.212% |
| CSL Limited | 3.7 Billion USD | 103.441% |
| Halberd Corporation | -75.05 Thousand USD | -169621.519% |
| Enzolytics Inc. | -2.14 Million USD | -5827.774% |
| Resverlogix Corp. | -12.74 Million USD | -899.106% |
| Affymax, Inc. | -15.04 Million USD | -746.577% |
| SYBLEU INC | -149.18 Thousand USD | -85284.1% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -3920.359% |
| argenx SE | -425.04 Million USD | 70.033% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -129.473% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -12100.766% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -7965.065% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -3640.875% |
| AVAX Technologies, Inc. | 6.69 Million USD | 2003.157% |
| Zenith Capital Corp. | -8.94 Million USD | -1324.31% |
| Genscript Biotech Corporation | -415.79 Million USD | 69.365% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -731063.538% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -5087.762% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -74167.589% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -131.709% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -4290.383% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -12844.018% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -6732.12% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -10041.401% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -6253.688% |
| BioStem Technologies, Inc. | -7.77 Million USD | -1537.441% |
| ONE Bio Corp. | 13.68 Million USD | 1031.006% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -70085.415% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -9438.194% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -11223.257% |
| Agentix Corp. | -1.37 Million USD | -9185.616% |
| LadRx Corporation | -3.82 Million USD | -3231.288% |
| Cell Source, Inc. | -4.32 Million USD | -2844.874% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -30557.626% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -18442.252% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -18442.252% |
| NovAccess Global Inc. | -2.46 Million USD | -5063.697% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -4263.023% |
| Itoco Inc. | -919.14 Thousand USD | -13758.172% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -2905.275% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -11283.021% |
| Kadimastem Ltd | -3.04 Million USD | -4089.655% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -48567.691% |
| CytoDyn Inc. | -18.05 Million USD | -605.372% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -505962.773% |
| Mobile Lads Corp. | -554.55 Thousand USD | -22869.254% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -57777.662% |
| Qrons Inc. | -643.67 Thousand USD | -19688.807% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -22455.483% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -5612.238% |
| Rebus Holdings, Inc. | -664 Thousand USD | -19083.133% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -6912.861% |
| International Stem Cell Corporation | -663 Thousand USD | -19112.066% |
| Bioxytran, Inc. | -3.82 Million USD | -3234.322% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -241875.684% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -626134.022% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -251.227% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -7772.435% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -17210.402% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -3994.375% |
| Neutra Corp. | -229.48 Thousand USD | -55404.911% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -626.244% |
| PureTech Health plc | -146.19 Million USD | 12.875% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -492.691% |
| IXICO plc | -1.43 Million USD | -8764.022% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -1242.071% |
| Gelesis Holdings, Inc. | -121.8 Million USD | -4.573% |
| CSL Limited | 3.81 Billion USD | 103.341% |
| Cellectis S.A. | -108.85 Million USD | -17.012% |